Clinical Trial Update: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial from AstraZeneca is evaluating novel drug combinations in participants with locally advanced unresectable or metastatic gastric cancer and gastr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Snippet

Sponsor: AstraZeneca | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING